Detalhe da pesquisa
1.
Ixazomib, lenalidomide, and dexamethasone combination in "real-world" clinical practice in patients with relapsed/refractory multiple myeloma.
Ann Hematol;
101(1): 81-89, 2022 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34550463
2.
Real-world effectiveness and safety of daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
Neoplasma;
68(3): 626-630, 2021 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33567854